• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Jounce Therapeutics Inc.

    5/4/23 7:29:32 AM ET
    $JNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNCE alert in real time by email
    S-8 POS 1 jnce05032023forms-8postxef.htm S-8 POS Document

    As filed with the Securities and Exchange Commission on May 4, 2023

    Registration No. 333-215794
    Registration No. 333-223519
    Registration No. 333-230088
    Registration No. 333-236687
    Registration No. 333-253496
    Registration No. 333-263215
    Registration No. 333-270481
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-215794
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223519
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230088
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-236687
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-253496
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263215
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270481
     
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
     
    JOUNCE THERAPEUTICS, INC.
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware 45-4870634
    (State or other jurisdiction of
    incorporation or organization)
     
    (IRS employer
    identification number)

    780 Memorial Drive
    Cambridge, Massachusetts 02139
    (Address of Principal Executive Offices, including Zip Code)
     
     
    Jounce Therapeutics, Inc. 2013 Stock Option and Grant Plan
    Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan
    Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan
    Stock Option Inducement Award
    (Full title of the Plans)
     
    Michael Hearne
    Chief Financial Officer
    Jounce Therapeutics, Inc.
    4747 Executive Drive, Suite 210
    San Diego, California 92121
    (858) 281-5372

    (Name, Address and Telephone Number, including Area Code, of Agent for Service)

    Copies to:

    Ryan A. Murr



    James J. Moloney
    Gibson, Dunn & Crutcher LLP
    555 Mission Street, 30th Floor
    San Francisco, California 94105
    (415) 393-8200

    Christopher Comeau
    Ropes & Gray LLP
    Prudential Tower, 800 Boylston Street
    Boston, Massachusetts 02199
    (671) 951-7809
     
     
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer ☐  Accelerated filer ☐
    Non-accelerated filer ☒  Smaller reporting company ☒
       Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
     

    EXPLANATORY NOTE
    DEREGISTRATION OF UNSOLD SECURITIES
    These Post-Effective Amendments (the “Post-Effective Amendments”) filed by Jounce Therapeutics, Inc., a Delaware corporation (the “Registrant”), to deregister all shares of the Registrant’s common stock, $0.001 par value per share (the “Shares”), remaining unissued under the following Registration Statements on Form S-8 (each, a “Registration Statement”, and collectively, the “Registration Statements”) filed by the Registrant with the U.S. Securities and Exchange Commission (the “Commission”).
     
     • 
    Registration Statement on Form S-8 (No. 333-215794) pertaining to the registration of (i) 4,289,693 Shares issuable under the Jounce Therapeutics, Inc. 2013 Stock Option and Grant Plan, (ii) 1,753,758 Shares issuable under the Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan (the “2017 Plan”) and (iii) 302,000 Shares issuable under the Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan (the “2017 ESPP”).
      
    • 
    Registration Statement on Form S-8 (No. 333-223519) pertaining to the registration of (i) 1,290,609 Shares issuable under the 2017 Plan and (ii) 322,652 Shares issuable under the 2017 ESPP.
      
    • 
    Registration Statement on Form S-8 (No. 333-230088) pertaining to the registration of (i) 1,317,935 Shares issuable under the 2017 Plan and (ii) 329,483 Shares issuable under the 2017 ESPP.
      
    • 
    Registration Statement on Form S-8 (No. 333-236687) pertaining to the registration of (i) 1,349,526 Shares issuable under the 2017 Plan and (ii) 337,381 Shares issuable under the 2017 ESPP.
      
    • 
    Registration Statement on Form S-8 (No. 333-253496) pertaining to the registration of (i) 1,669,162 Shares issuable under the 2017 Plan and (ii) 417,290 Shares issuable under the 2017 ESPP.
      
    • 
    Registration Statement on Form S-8 (No. 333-263215) pertaining to the registration of (i) 2,050,601 Shares issuable under the 2017 Plan, (ii) 512,650 Shares issuable under the 2017 ESPP and (iii) the inducement stock option award of nonqualified stock options to purchase 225,000 shares of Common Stock granted by the Registrant to an employee of the Registrant on May 1, 2021.
      
    • 
    Registration Statement on Form S-8 (No. 333-270481) pertaining to the registration of (i) 2,067,769 Shares issuable under the 2017 Plan and (ii) 516,942 Shares issuable under the 2017 ESPP.



    The Registrant is filing these Post-Effective Amendments to withdraw and remove any unissued and unsold securities issuable by Registration pursuant to the above-referenced Registration Statements.
    On March 26, 2023, the Registrant entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), and Concentra Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on May 3, 2023, Merger Sub was merged with and into the Registrant with the Registrant surviving as a wholly owned subsidiary of Parent (the “Merger”). In the Merger, each share of Common Stock (other than Excluded Shares or Dissenting Shares, each as defined in the Merger Agreement) (the “Shares”) was cancelled and converted into the right to receive (i) $1.85 per Share, net to the seller, without interest and subject to any withholding of taxes, plus (ii) one non-transferrable contractual contingent value right per Share.
    In connection with the effectiveness of the Merger, the offerings pursuant to the Registration Statements have been terminated. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all Shares registered under the Registration Statements but not sold under the Registration Statements.






    SIGNATURE
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 4, 2023. No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance on Rule 478 of the Securities Act of 1933, as amended.
     
    JOUNCE THERAPEUTICS, INC.
    /s/ Michael Hearne
    Name: Michael Hearne
    Title: Chief Financial Officer


    Get the next $JNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNCE

    DatePrice TargetRatingAnalyst
    5/11/2022$15.00 → $7.00Outperform → Neutral
    Robert W. Baird
    5/6/2022$15.00 → $20.00Outperform → Strong Buy
    Raymond James
    3/16/2022$17.00Outperform
    SMBC Nikko
    2/4/2022Market Perform → Outperform
    Cowen & Co.
    11/5/2021$10.00 → $15.00Outperform
    Raymond James
    9/14/2021$10.00Market Perform → Outperform
    Raymond James
    More analyst ratings

    $JNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jounce Therapeutics Announces Closing of Tender Offer

      CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC ("Concentra"), through its wholly owned subsidiary Concentra Merger Sub, Inc. ("Concentra Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 per share in cash plus a non-tradeable contingent value right (a "CVR") per share. The $1.85 per share upfront consideration represents a premium of approximately

      5/3/23 8:35:17 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce's Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination"). Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Conc

      4/3/23 2:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfront con

      3/27/23 9:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Financials

    Live finance-specific insights

    See more
    • Redx and Jounce Announce Recommended Business Combination

      Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the

      2/23/23 2:30:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Reports Third Quarter 2022 Financial Results

      - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with $130.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quart

      11/10/22 7:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

      CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Me

      10/27/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Concentra Biosciences, Llc

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:38:21 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tang Kevin C

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:37:26 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Concentra Biosciences, Llc claimed ownership of 36,367,727 shares

      3 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:35:30 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jounce Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Jounce Therapeutics from Outperform to Neutral and set a new price target of $7.00 from $15.00 previously

      5/11/22 6:18:27 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Jounce Therapeutics from Outperform to Strong Buy and set a new price target of $20.00 from $15.00 previously

      5/6/22 7:22:10 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SMBC Nikko initiated coverage on Jounce Therapeutics with a new price target

      SMBC Nikko initiated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $17.00

      3/16/22 7:50:25 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

      CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. "It's incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring over 20 years of biotechnology industry experience, but he also comes with a unique position as an early employee of the company at its inception," said Richard Murray, Ph.D., chief executive offic

      9/15/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer. "The addition of Dmitri to the Jounce team comes at an exciting juncture in our company development," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Dmitri brings a broad knowledge of contemporary immuno-oncology approaches, tumor immunology and cancer biology. His expertise with preclinical target discovery and first-in-human research will

      4/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors

      CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors. “We are thrilled to welcome Luisa to our board of directors,” said Perry Karsen, chairman of the board of Jounce Therapeutics. “Luisa brings over 20 years of experience in the healthcare industry, specifically in immunology and immuno-oncology, and we look forward to the unique and valuable perspective that her strategic leadership will bring to Jounce.” Dr. Salter-Cid currently serves a

      2/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/14/24 8:50:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jounce Therapeutics Inc.

      SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/9/24 4:05:34 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/2/24 12:28:25 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Jounce Therapeutics Inc.

      15-12G - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/15/23 7:40:24 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:08 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care